Voyager Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
Voyager Therapeutics, Inc. (VYGR) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price of $7.25 per share for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice · last filed 2026-08-06
- Voyager Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2025-03-31 was $6.14, a 50.00% decline year-over-year.
- Voyager Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $12.28, a 126.57% increase year-over-year.
- Voyager Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2023-03-31 was $5.42, a 58.69% decline year-over-year.
- Voyager Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for the quarter ending 2022-03-31 was $13.12, a 6.35% decline year-over-year.
- Voyager Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2025 was $7.15, a 34.88% decline from fiscal 2024.
- Voyager Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2024 was $10.98, a 39.69% increase from fiscal 2023.
- Voyager Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2023 was $7.86, a 40.23% decline from fiscal 2022.
- Voyager Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, forfeitures and expirations in period, weighted average exercise price for fiscal 2022 was $13.15, a 3.17% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|---|
| 2026-06-30 | $7.25 10-Q · filed 2026-08-06 | ||||
| 2025-12-31 | $7.15 10-K · filed 2026-03-09 | ||||
| 2025-09-30 | $7.27 10-Q · filed 2025-11-10 | ||||
| 2025-06-30 | $7.01 10-Q · filed 2025-08-06 | ||||
| 2025-03-31 | $6.14 10-Q · filed 2026-05-07 | $7.41 10-Q · filed 2025-05-06 | |||
| 2024-12-31 | $10.98 10-K · filed 2025-03-11 | ||||
| 2024-09-30 | $11.69 10-Q · filed 2024-11-12 | ||||
| 2024-06-30 | $14.40 10-Q · filed 2024-08-06 | ||||
| 2024-03-31 | $12.28 10-Q · filed 2024-05-13 | ||||
| 2023-12-31 | $7.86 10-K · filed 2024-02-28 | ||||
| 2023-09-30 | $9.60 10-Q · filed 2023-11-06 | ||||
| 2023-06-30 | $9.71 10-Q · filed 2023-08-03 | ||||
| 2023-03-31 | $5.42 10-Q · filed 2023-05-09 | ||||
| 2022-12-31 | $13.15 10-K · filed 2023-03-07 | ||||
| 2022-09-30 | $13.22 10-Q · filed 2022-11-08 | ||||
| 2022-06-30 | $12.42 10-Q · filed 2022-08-04 | ||||
| 2022-03-31 | $13.12 10-Q · filed 2022-05-04 | ||||
| 2021-12-31 | $13.58 10-K · filed 2022-03-08 | ||||
| 2021-09-30 | $13.41 10-Q · filed 2021-11-02 | ||||
| 2021-06-30 | $12.96 10-Q · filed 2021-08-09 | ||||
| 2021-03-31 | $14.01 10-Q · filed 2021-05-10 | ||||
| 2020-12-31 | $17.33 10-K · filed 2021-02-25 | ||||
| 2020-09-30 | $16.99 10-Q · filed 2020-11-09 | ||||
| 2020-06-30 | $16.59 10-Q · filed 2020-08-10 | ||||
| 2020-03-31 | $15.66 10-Q · filed 2020-05-06 | ||||
| 2019-12-31 | $12.12 10-K · filed 2020-03-03 | ||||
| 2019-09-30 | $15.50 10-Q · filed 2019-11-06 | ||||
| 2019-06-30 | $14.05 10-Q · filed 2019-08-09 | ||||
| 2019-03-31 | $12.93 10-Q · filed 2019-05-07 | ||||
| 2018-12-31 | $16.13 10-K · filed 2019-02-26 | ||||
| 2018-09-30 | $16.20 10-Q · filed 2018-11-07 | ||||
| 2018-06-30 | $15.42 10-Q · filed 2018-08-07 | ||||
| 2018-03-31 | $14.52 10-Q · filed 2018-05-10 | ||||
| 2017-09-30 | $10.63 10-Q · filed 2017-11-02 | ||||
| 2017-06-30 | $10.08 10-Q · filed 2017-08-08 | ||||
| 2017-03-31 | $9.93 10-Q · filed 2017-05-09 | ||||
| 2016-09-30 | $10.07 10-Q · filed 2016-11-10 | ||||
| 2016-06-30 | $9.93 10-Q · filed 2016-08-11 | ||||
| 2016-03-31 | $9.53 10-Q · filed 2016-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |